Kynurenic acid levels in cerebrospinal fluid from patients with alzheimer's disease or dementia with lewy bodies

International Journal of Tryptophan Research

Volumn 7, Issue 1, 2014, Pages 1-7

  Wennström, Malin ^a   Nielsen, Henrietta M ^b   Orhan, Funda ^c   Londos, Elisabet ^a   Minthon, Lennart ^a   Erhardt, Sophie ^c  

^a LUND UNIVERSITY   (Sweden)

^b MAYO CLINIC   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alzheimer's disease; Astrocyte markers; Cognition; Dementia with lewy bodies; Inflammation; Kynurenic acid

Indexed keywords

EID: 84900032495     PISSN: None     EISSN: 11786469     Source Type: Journal    
DOI: 10.4137/IJtr.s13958     Document Type: Article

References (57)

1. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995;16(3):271-278; discussion 8-84.
2. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65(12):1863-72.
3. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41(4):479-86.
4. Sokolowski JD, Mandell JW. Phagocytic clearance in neurodegeneration. Am J Pathol. 2011;178(4):1416-28. [Research Support, N.I.H., Extramural Review].
5. Imamura K, Hishikawa N, Ono K, et al. Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains. Acta Neuropathol (Berl). 2005;109(2):141-50. [Comparative Study].
6. Mackenzie IR. Actived microglia in dementia with Lewy bodies. Neurology. 2000;55(1):132-4.
7. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131-44.
8. Nielsen HM, Londos E, Minthon L, Janciauskiene SM. Soluble adhesion molecules and angiotensin-converting enzyme in dementia. Neurobiol Dis. 2007;26(1):27-35.
9. Nielsen HM, Minthon L, Londos E, et al. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology. 2007;69(16):1569-79.
10. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996;47(2):425-32.
11. Kravitz BA, Corrada MM, Kawas CH. Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old. Alzheimers Dement. 2009;5(4):318-23. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
12. van Exel E, Eikelenboom P, Comijs H, et al. Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease. Arch Gen Psychiatry. 2009;66(11):1263-70. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
13. Hartai Z, Juhasz A, Rimanoczy A, et al. Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease. Neurochem Int. 2007;50(2):308-13. [Research Support, Non-U.S. Gov't].
14. Duleu S, Mangas A, Sevin F, Veyret B, Bessede A, Geffard M. Circulating antibodies to IDO/THO pathway metabolites in Alzheimer's disease. Int J Alzheimers Dis. 2010;2010:501541.
15. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-9. [Consensus Development Conference, NIH Research Support, Non-U.S. Gov't].
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-44. [Guideline Practice Guideline].
17. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113-24.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-98.
19. Heyes MP, Quearry BJ. Quantification of kynurenic acid in cerebrospinal fluid: effects of systemic and central L-kynurenine administration. J Chromatogr. 1990;530(1):108-115.
20. Linderholm KR, Skogh E, Olsson SK, et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull. 2012;38(3):426-32. [Research Support, U.S. Gov't, Non-P.H.S.].
21. Gulaj E, Pawlak K, Bien B, Pawlak D. Kynurenine and its metabolites in Alzheimer's disease patients. Adv Med Sci. 2010;55(2):204-11. [Research Support, Non-U.S. Gov't].
22. Kepplinger B, Baran H, Kainz A, Ferraz-Leite H, Newcombe J, Kalina P. Age-related increase of kynurenic acid in human cerebrospinal fluid - IgG and beta2-microglobulin changes. Neurosignals. 2005;14(3):126-35. [Comparative Study Research Support, Non-U.S. Gov't].
23. Nilsson LK, Nordin C, Jonsson EG, Engberg G, Linderholm KR, Erhardt S. Cerebrospinal fluid kynurenic acid in male and female controls - correlation with monoamine metabolites and influences of confounding factors. J Psychiatr Res. 2007;41(1-2):144-51. [Research Support, Non-U.S. Gov't].
24. Olsson SK, Samuelsson M, Saetre P, et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J Psychiatry Neurosci. 2010;35(3):195-9. [Research Support, Non-U.S. Gov't].
25. Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE. Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol. 2009;19(3):392-8. [Research Support, Non-U.S. Gov't].
26. Abraham CR. Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer's disease. Neurobiol Aging. 2001;22(6):931-6. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review].
27. Heyes MP, Saito K, Crowley JS, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and noninflammatory neurological disease. Brain. 1992;115(pt 5):1249-73. [Research Support, U.S. Gov't, Non-P.H.S.].
28. Atlas A, Gisslen M, Nordin C, Lindstrom L, Schwieler L. Acute psychotic symptoms in HIV-1 infected patients are associated with increased levels of kynurenic acid in cerebrospinal fluid. Brain Behav Immun. 2007;21(1):86-91. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
29. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13(7):465-77. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review].
30. Rose DP, Braidman IP. Excretion of tryptophan metabolites as affected by pregnancy, contraceptive steroids, and steroid hormones. Am J Clin Nutr. 1971;24(6):673-83. [Review].
31. Zhu WH, Lu CZ, Huang YM, Link H, Xiao BG. A putative mechanism on remission of multiple sclerosis during pregnancy: estrogen-induced indoleamine 2,3-dioxygenase by dendritic cells. Mult Scler. 2007;13(1):33-40. [Research Support, Non-U.S. Gov't].
32. Nelson PT, Schmitt FA, Jicha GA, et al. Association between male gender and cortical Lewy body pathology in large autopsy series. J Neurol. 2010;257(11):1875-81.
33. Kaluza J, Krupinski J, Kumar P, Kumar S, Wang JM. VCAM-1 expression on reactive and tumour astrocytes. Folia Histochem Cytobiol. 1994;32(1):17-20. [Research Support, Non-U.S. Gov't].
34. Akiyama H, Kawamata T, Yamada T, Tooyama I, Ishii T, McGeer PL. Expression of intercellular adhesion molecule (ICAM)-1 by a subset of astrocytes in Alzheimer disease and some other degenerative neurological disorders. Acta Neuropathol (Berl). 1993;85(6):628-34. [Research Support, Non-U.S. Gov't].
35. Erhardt S, Lim CK, Linderholm KR, et al. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology. 2013;38(5):743-52. [Research Support, Non-U.S. Gov't].
36. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-98.
37. Potter MC, Elmer GI, Bergeron R, et al. Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology. 2010;35(8):1734-42. [In Vitro Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
38. Alexander KS, Pocivavsek A, Wu HQ, Pershing ML, Schwarcz R, Bruno JP. Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine. Neuroscience. 2013;238:19-28.
39. Pocivavsek A, Wu HQ, Elmer GI, Bruno JP, Schwarcz R. Pre-and postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur J Neurosci. 2012;35(10):1605-12. [Research Support, N.I.H., Extramural].
40. Forrest CM, Mackay GM, Oxford L, et al. Kynurenine metabolism predicts cognitive function in patients following cardiac bypass and thoracic surgery. J Neurochem. 2011;119(1):136-52. [Research Support, Non-U.S. Gov't].
41. Zetterberg H, Mattsson N, Shaw LM, Blennow K. Biochemical markers in Alzheimer's disease clinical trials. Biomark Med. 2010;4(1):91-8. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review].
42. Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, Guillemin GJ. The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One. 2009;4(7):e6344. [Research Support, Non-U.S. Gov't].
43. Pierozan P, Zamoner A, Soska AK, et al. Acute intrastriatal administration of quinolinic acid provokes hyperphosphorylation of cytoskeletal intermediate filament proteins in astrocytes and neurons of rats. Exp Neurol. 2010;224(1):188-96. [Research Support, Non-U.S. Gov't].
44. Wu W, Nicolazzo JA, Wen L, et al. Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain. PLoS One. 2013;8(4):e59749.
45. Ganong AH, Cotman CW. Kynurenic acid and quinolinic acid act at N-methyl-d-aspartate receptors in the rat hippocampus. J Pharmacol Exp Ther. 1986;236(1):293-9. [In Vitro Research Support, U.S. Gov't, Non-P.H.S.]
46. Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia. 2005;49(1):15-23. [Research Support, Non-U.S. Gov't].
47. Pemberton LA, Kerr SJ, Smythe G, Brew BJ. Quinolinic acid production by macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha. J Interferon Cytokine Res. 1997;17(10):589-95.
48. Guillemin GJ, Croitoru-Lamoury J, Dormont D, Armati PJ, Brew BJ. Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes. Glia. 2003;41(4):371-81. [Research Support, Non-U.S. Gov't].
49. Ting KK, Brew BJ, Guillemin GJ. Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease. J Neuroinflammation. 2009;6:36. [Research Support, Non-U.S. Gov't].
50. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol. 2005;31(4):395-404. [Research Support, Non-U.S. Gov't].
51. Lee SJ, Benveniste EN. Adhesion molecule expression and regulation on cells of the central nervous system. J Neuroimmunol. 1999;98(2):77-88. [Research Support, U.S. Gov't, P.H.S. Review].
52. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313-26. [Research Support, N.I.H., Extramural Review].
53. Adams DH, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet. 1994;343(8901):831-6. [Research Support, Non-U.S. Gov't Review].
54. Roebuck KA, Finnegan A. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol. 1999;66(6):876-88. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review].
55. Leeuwenberg JF, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Jeunhomme TM, et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology. 1992;77(4):543-9. [Research Support, Non-U.S. Gov't].
56. Owe-Young R, Webster NL, Mukhtar M, et al. Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance and neurotoxicity. J Neurochem. 2008;105(4):1346-57. [Comparative Study Research Support, Non-U.S. Gov't].
57. Barth MC, Ahluwalia N, Anderson TJ, et al. Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. J Biol Chem. 2009;284(29):19189-95. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].